PSMA PET may lead to misdiagnosis, unnecessary changes in treatment

PET imaging is a common tool to establish the stage of a patient’s prostate cancer, but new research raises questions about its association with misdiagnosis and unnecessary changes in therapies. Benign tissues in the kidney, bowels and salivary glands may show increased prostate-specific membrane antigen (PSMA) expression, prompting experts to caution against relying solely on PSMA PET.

"It is important that nuclear medicine physicians be aware of this pitfall, as the interpretation of PSMA PET scans may have a substantial impact on therapy guidance," said Christoph Rischpler, MD, of Germany's Technical University in Munich, in a statement from the Society of Nuclear Medicine & Molecular Imaging. His team’s findings were published online Sept. 7 in the Journal of Nuclear Medicine.

Researchers, in looking at 407 patients and comparing findings to adjacent lymph node metastases, found the uptake was above background levels in 401 (98.5 percent) participants.

 

Despite the high rate of uptake, PSMA PET is still a valuable tool in diagnosing prostate cancer and determining its stage of development. These findings, according to the authors, mean physicians should be aware that misinterpretations based on benign tissues are possible.  

“[PSMA]-ligand uptake in sympathetic ganglia is a very common and important pitfall,” Rischpler et al. wrote. “However, on the basis of different anatomic configuration and uptake characteristics (intensity and intraindividual correlation of uptake), differentiation from possible adjacent lymph node metastases should be easily accomplishable.”

Watch a video of Rischpler summarizing findings from his team of researchers here.

""
Nicholas Leider, Managing Editor

Nicholas joined TriMed in 2016 as the managing editor of the Chicago office. After receiving his master’s from Roosevelt University, he worked in various writing/editing roles for magazines ranging in topic from billiards to metallurgy. Currently on Chicago’s north side, Nicholas keeps busy by running, reading and talking to his two cats.

Around the web

The nuclear imaging isotope shortage of molybdenum-99 may be over now that the sidelined reactor is restarting. ASNC's president says PET and new SPECT technologies helped cardiac imaging labs better weather the storm.

CMS has more than doubled the CCTA payment rate from $175 to $357.13. The move, expected to have a significant impact on the utilization of cardiac CT, received immediate praise from imaging specialists.

The all-in-one Omni Legend PET/CT scanner is now being manufactured in a new production facility in Waukesha, Wisconsin.

Trimed Popup
Trimed Popup